https://www.sciencedirect.com/science/article...1926000190
Highlights
•
A 40-year-old female patient was diagnosed with triple negative breast cancer
•
Despite standard treatment she rapidly progressed with lung and liver metastases
•
The patient subsequently received third-line atezolizumab plus leronlimab
•
Following leronlimab PD-L1 expression on CTCs and CAMLs increased significantly
•
She remains alive with no evidence of disease >60 months after starting leronlimab